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Objectives
Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming
neuropsychological assessment. Screening tools are needed to identify when neuropsychological
referral is indicated. We examined the positive and negative predictive values (PPVs and NPVs,
respectively) of the three European AIDS Clinical Society (EACS) screening questions in identifying NCI.
Methods
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study recruited patients
aged ≥45 years enrolled in the Swiss HIV Cohort Study between 1 May 2013 and 30 November 2016.
NAMACO participants (1) answered EACS screening questions, (2) underwent standardized
neuropsychological assessment and (3) completed self-report forms [Center for Epidemiologic Studies
Depression Scale (CES-D)] rating mood. NCI categories were defined using Frascati criteria. PPVs and
NPVs of the EACS screening questions in identifying NCI categories were calculated.
Results
Of 974 NAMACO participants with complete EACS screening question data, 244 (25.1%) expressed
cognitive complaints in answer to at least one EACS screening question, of whom 51.3% had NCI
(26.1% HIV-associated and 25.2% related to confounding factors). The PPV and NPV of the EACS
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screening questions in identifying HIV-associated NCI were 0.35 and 0.7, respectively. Restricting
analysis to NCI with functional impairment or related to confounding factors, notably depression,
the NPV was 0.90. Expressing cognitive complaints for all three EACS screening questions was
significantly associated with depression (P < 0.001).
Conclusions
The EACS screening questions had an NPV of 0.7 for excluding patients with HIV-associated NCI
as defined by Frascati criteria. The PPV and NPV may improve if NCI diagnoses are based on new
criteria.
Keywords: screening, neurocognitive impairment, predictive values, neuropsychological testing, HIV
and aging
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Introduction
In the era of potent antiretroviral therapy (ART), HIV-as-
sociated neurocognitive impairment (NCI) remains a clini-
cal problem, particularly in an aging population of
people living with HIV (PLWH). NCI is also a diagnostic
problem, as standardized neuropsychological testing of
specific cognitive domains is time-consuming, costly and
not available at all centres [1].
Since NCI was first identified as an entity, ART has
become more effective and patients now live well and for
longer. With this, NCI categories were redefined in 2007,
according to the Frascati criteria, into asymptomatic neu-
rocognitive impairment (ANI; mild to moderate cognitive
deficits without functional impairment), mild neurocogni-
tive disorders (MND; mild to moderate cognitive deficits
with functional impairment) and HIV-associated dementia
(HAD; moderate to severe cognitive deficits with func-
tional impairment) [2]. Labelling NCI as ‘HIV-associated’
requires the exclusion of confounding factors, including
organic brain pathology, substance misuse and psychi-
atric disorders, notably depression [2,3].
The Frascati criteria are, to date, the only published
criteria for categorizing NCI that have been arrived at by
consensus. Whilst such criteria enable comparison of the
results of cohort studies examining NCI in different
patient populations, limitations have been described.
Patients with mild cognitive deficits classified as ANI, for
example, have been reclassified as cognitively normal
when assessed using other criteria [4]. Equally, patients at
the moderate end of the ANI spectrum may be classified
as having ANI rather than MND as a consequence of the
low sensitivity of testing methods for functional impair-
ment. Using Frascati criteria alone, it is difficult to pre-
dict which individuals with ANI will deteriorate. This is
important given the CNS HIV Anti-Retroviral Therapy
Effects Research (CHARTER) study group observation that
ANI diagnosis conferred a two- to six-fold increase in the
risk of earlier development of symptomatic NCI [5].
Potential NCI screening tools more rapid than neuropsy-
chological testing (minutes rather than hours) have been
examined [6–10]. However, as several studies were pub-
lished prior to the 2007 Frascati criteria [6] or were con-
ducted among younger patients or to identify more severe
NCI stages [10] in advanced disease [11], or without
excluding patients with depression [7], it is not possible to
confidently apply these to aging populations of PLWH who
have well-controlled infection on modern ART.
The European AIDS Clinical Society (EACS) recom-
mends a simple tool to identify which patients merit for-
mal neuropsychological testing, using three cognitive
symptom questions which cover memory loss, mental
slowing and attention difficulties [12]. The questions are
taken from a paper by Simioni et al. which assessed
patients with cognitive complaints for the presence of
NCI [13] and are included in the EACS NCI assessment
algorithm at the time of writing [14]. In Switzerland,
PLWH enrolled in the Swiss HIV Cohort Study (SHCS)
[15] are screened for NCI once a year using the EACS
screening questions. Recruiting SHCS patients to the Neu-
rocognitive Assessment in the Metabolic and Aging
Cohort (NAMACO) study has enabled a review of the
value of the EACS screening question scores in identify-
ing NCI in PLWH. The aim of this study was to determine
the positive and negative predictive values (PPVs and
NPVs, respectively) of these questions.
Methods
Study design
The NAMACO study is an ongoing, prospective, longitu-
dinal, multicentre and multilingual (German, French and
Italian) study included within the SHCS, created to inves-
tigate NCI in a well-treated and aging population of
PLWH.
SHCS patients aged ≥ 45 years and followed up at one
of seven university-affiliated hospital centres (Bern, Basel,
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Geneva, Lausanne, St-Gallen, Lugano and Zurich) were
invited to participate in the NAMACO study between 1
May 2013 and 30 November 2016, resulting in a cohort
of 981 participants [16]. The ethics committees of all par-
ticipating hospital centres approved the NAMACO study
protocol. All NAMACO participants signed informed con-
sent forms prior to inclusion.
Neuropsychological evaluation
NAMACO participants were asked the three EACS screen-
ing questions on cognitive function at baseline (inclusion)
by their HIV clinicians, as part of a standard SHCS clinic
visit: (1) Do you experience frequent memory loss? (2) Do
you feel that you are slower when reasoning, planning
activities or solving problems? (3) Do you have difficul-
ties paying attention? For each question, the response
options were: never, hardly ever or yes, definitely.
All participants then underwent standardized neuropsy-
chological assessment by neuropsychologists, examining
seven cognitive domains based on the International Net-
work for Strategic Initiatives in Global HIV Trials
(INSIGHT) Strategic Timing of AntiRetroviral Treatment
(START) study [17]: motor skills, speed of information
processing, attention and working memory, executive
function, verbal episodic memory, language, and sensory
and perceptual skills (Table S1). The complete battery
required 90 min to perform in patients with no deficits.
The raw score for each neuropsychological test was con-
verted to a demographically adjusted standard score (z-
score) as described elsewhere [16].
Participants also completed self-report forms on func-
tional ability (Lawton’s Instrumental Activities of Daily
Living and Patient’s Assessment of Own Functioning
Inventory questionnaire) and mood [Center for Epidemio-
logic Studies Depression Scale (CES-D)]. Functional
impairment was defined as difficulties in at least two
items out of eleven. Depressive symptoms were consid-
ered as mild for CES-D scores 16–26, and severe for CES-
D scores ≥ 27.
Frascati criteria were used to categorize participants as
having: no NCI (normal neuropsychological examination),
ANI, MND, HAD or non-HIV-associated NCI (‘other’,
when NCI could be explained by confounding factors:
substance misuse, psychiatric disorders including CES-
D ≥ 27, ART toxicity, central nervous system opportunis-
tic infection, stroke or trauma). The distinction between
HIV-associated NCI and NCI related to confounding fac-
tors was based on the clinical judgment of the neuropsy-
chologists performing the neuropsychological assessment.
Although the Frascati criteria have limitations as
described in the Introduction, they were the only
published criteria arrived at by consensus at the time of
study recruitment (2013–2016).
Statistical analysis
The association between cognitive complaints and NCI
category was examined using the Pearson v2 test. Cogni-
tive complaints were defined as being present when the
patient answered yes, definitely and were analysed as a
binary variable (yes, definitely answered to at least one
EACS screening question). Predictive values of answering
yes, definitely to at least one EACS screening question
were assessed in 2 9 2 contingency tables by the ability
to detect or exclude (1) all NCI (HIV- and non-HIV-asso-
ciated, with and without functional impairment), (2) HIV-
associated NCI and (3) NCI with functional impairment
either of HIV origin (MND and HAD) or not (‘other’). Cog-
nitive complaints in relation to depressive symptoms
(CES-D score) were further examined using the Wil-
coxon–Mann–Whitney test.
Cognitive complaints were also examined using receiver
operating characteristic (ROC) curves by summing the three
EACS screening questions (never = 0, hardly ever = 1, and
yes, definitely = 2) and taking integer values between 0
and 6 as a pseudo-continuous means of detecting or
excluding NCI, HIV-associated NCI, NCI with functional
impairment and non-HIV-associated NCI (other).
Statistical analyses were conducted using R Develop-
ment Core Team version 3.2 2015 (R Foundation for Sta-
tistical Computing, Vienna, Austria; www.R-project.org).
Results
The baseline characteristics of the 981 participants
enrolled in the NAMACO study have been presented else-
where [16]. Briefly, of the 981 participants, 782 (79.7%)
were male, 899 (91.7%) were Caucasian and 627 (63.9%)
were aged > 50 years (mean  SD age 54.5  7.5 years).
Most (96.2%) had viral loads < 50 copies/mL; the median
nadir CD4 count was 180 cells/lL (IQR 74, 270 cells/lL).
Of the 964 participants (98.3%) with complete NCI data,
127 (13.2%) were categorized as having non-HIV-associ-
ated NCI (‘other’) (Table 1). Of these participants, several
had more than one confounding factor: 79 participants
(62.2%) had a psychiatric disorder, mostly depression, 41
(32.3%) had organic brain pathology (history of trauma,
stroke, opportunistic infection or unspecified pathology),
and 26 (20.5%) had a history of substance misuse.
Of the 974 participants with complete EACS screening
question data (99.3%), the prevalence of cognitive
© 2019 The Authors.
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complaints (answering yes to at least one EACS screening
question) was 25.1% (244/974): 21% pertaining to mem-
ory loss, 8.3% to mental slowing, and 12.6% to attention
deficits. SHCS patients who were eligible for the
NAMACO study but not enrolled (n = 2718) presented a
lower prevalence of cognitive complaints: 14.4% pertain-
ing to memory loss (P < 0.001), 7% to mental slowing
(P = 0.19) and 9.8% to attention deficits (P = 0.02). The
neurocognitive diagnoses in these participants, presented
according to Frascati criteria, and the presence or absence
of neurocognitive complaints are shown in Table 1 and
Figure 1. The presence of NCI was significantly associated
with cognitive complaints (P < 0.001), with NCI in 122/
238 participants (51.3%) with cognitive complaints com-
pared to 264/719 participants (36.7%) without com-
plaints. The PPV and NPV of answering yes, definitely to
at least one EACS screening question for diagnosing NCI
(HIV-associated with or without ‘other’ causes) or symp-
tomatic NCI (excluding ANI and normal neurocognitive
assessment) are shown in Table 2.
The presence of cognitive complaints among NAMACO
participants was associated with low mood as measured
by CES-D score. Having severe depression (CES-D
score > 27), present in 90/973 participants with complete
CES-D score data (9.2%), was significantly associated
with answering yes, definitely to all three EACS screening
questions (v2 test, P < 0.001). However, even patients
answering yes, definitely to at least one EACS screening
question had higher median CES-D scores than those
having no complaints [median 14 (IQR 7–24) versus med-
ian 5 (IQR 4–6); P < 0.0001].
A continuous model, defining complaints in terms of
the sum of answers to the three EACS screening ques-
tions, gave areas under the ROC curves (AUCs) of 0.57
[95% confidence interval (CI) 0.53–0.61] for distinguish-
ing NCI from no NCI, 0.52 (95% CI 0.47–0.56) for
distinguishing HIV-associated NCI from no NCI, and 0.7
(95% CI 0.64–0.75) for distinguishing MND, HAD or
‘other’ from ANI or no NCI (Figure S1).
Discussion
In this large cohort of patients with well-controlled HIV
infection, one quarter had cognitive complaints, most fre-
quently related to memory loss. The presence of NCI,
diagnosed upon formal neuropsychological assessment,
was significantly associated with having cognitive com-
plaints. Having cognitive complaints in turn was signifi-
cantly associated with low mood and depression. PPVs of
the EACS screening questions were poor (0.29–0.51) while
the NPV to exclude NCI varied between 0.63 and 0.9,
depending on NCI category.
This study has several strengths. The NAMACO study,
with over 900 participants, is one of the largest cohort
studies to examine NCI, and NAMACO participants are
highly characterized through links to the SHCS database.
Neuropsychological assessment was conducted by trained
neuropsychologists to enable inclusion of individuals less
able to complete assessments via computer. Assessment
was possible despite the study being conducted over three
linguistic regions of Switzerland, through neuropsycholo-
gists being fluent in the test language, an element vital
for the verbal aspect of testing [18]. Finally, the EACS
screening questions were asked by the patients’ own HIV
clinicians, so in a ‘real-life’ setting rather than as part of
neuropsychological testing.
The percentages of participants with cognitive com-
plaints and different categories of NCI differ from those
observed by Simioni et al. [13]. Although a similar per-
centage had complaints (25% in the current study com-
pared to 27% reported by Simioni et al.), the percentage
of patients with NCI among patients with and without
complaints was much higher, with HIV-associated NCI
(ANI, MND and HAD) reported in 84% of complaining
patients (52% with MND) and 64% of noncomplaining
patients (60% with ANI) [13]. This is likely to be related
to differences in inclusion criteria between the Simioni
et al. study and the NAMACO study. In the former,
patients from French-speaking Switzerland of any age
were recruited if they had cognitive symptoms; in the lat-
ter, patients from throughout Switzerland were recruited,
regardless of cognitive symptoms, provided they were
aged ≥ 45 years. Two other cohort studies have examined
the association between answers to the EACS screening
questions and NCI. The British Pharmacokinetic and Clin-
ical Observations in People over Fifty (POPPY) study
assessed cognitive function in 290 patients, with a med-
ian age of 57 years, using a computerized battery
Table 1 Neurocognitive diagnosis among study patients with cogni-
tive complaints, without cognitive complaints and overall
Neurocognitive
diagnosis
Patients with
complaints
(n = 238)*
Patients without
complaints
(n = 719)*
All
patients
(n = 964)*
Normal 116 (48.7) 455 (63.3) 574 (59.5)
ANI 54 (22.7) 193 (26.8) 249 (25.8)
MND 3 (1.3) 5 (0.7) 8 (0.8)
HAD 5 (2.1) 1 (0.1) 6 (0.6)
Other 60 (25.2) 65 (9) 127 (13.2)
Values shown are n (%). ANI, asymptomatic neurocognitive impairment;
HAD, HIV-associated dementia; MND, mild neurocognitive disorder; NCI,
neurocognitive impairment; other, neurocognitive impairment related to
confounders rather than associated with HIV infection.
*This number refers to the number of patients with complete European
AIDS Clinical Society screening question data and complete neurocogni-
tive assessment data.
© 2019 The Authors.
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(CogStateTM, London, UK) and found a weak association
between NCI, defined according to Frascati and other cri-
teria, and patient-reported outcome measures including
answers to the EACS screening questions [19]. The Dutch
TREVI study examined cognitive function in 388 patients,
with a mean age of 48 years, of whom 69 (17.8%) com-
pleted a neuropsychological assessment, and reported a
sensitivity and specificity of 82% and 24%, respectively,
for the EACS screening questions, which changed to 50
and 73% when used with the International HIV Dementia
Scale [20]. What our data add to these studies is the high
number of patients who underwent formal neuropsycho-
logical assessment and the strong association between
answering yes, definitely to the EACS screening questions
and depression. The relationship between NCI and depres-
sion in NAMACO study participants is the subject of
another paper (Santos et al., unpublished).
The high NPV (0.9) for excluding NCI with functional
impairment and non-HIV-associated NCI is of unclear
clinical value while the Frascati diagnosis of ANI is under
debate, and especially when this NPV was at the expense
of a low PPV (0.3). Individuals with ANI are potentially
heterogenous, ranging from near-normal to near-MND
within the ANI spectrum. If more robust criteria for
defining NCI could be agreed upon, for example, based
on quantitative neurocognitive domain z-scores, perhaps
the NPV of the EACS screening questions in excluding
cognitively normal and near-normal patients can be
reviewed. It should also be noted that patients with more
severe NCI (MND or HAD) may not have cognitive com-
plaints through anosognosia [21] and so clinical prudence
should be employed when applying any subjective
screening tool.
This study has limitations. First, the study was limited
to a Swiss cohort and our findings may not apply to
other populations. Secondly, NAMACO participants had
more cognitive complaints compared to eligible but non-
recruited SHCS patients, suggesting a possible selection
Fig. 1 Prevalence of neurocognitive impairment among all study participants, those with cognitive complaints and those without complaints.
NCI, neurocognitive impairment; ANI, asymptomatic neurocognitive impairment; MND, mild neurocognitive disorder; HAD, HIV-associated
dementia; other, neurocognitive impairment related to confounders other than those associated with HIV infection.
Table 2 Positive and negative predictive values (PPV and NPV, respectively) of answering ‘yes’ to at least one European Clinical AIDS Society
screening question as a screening tool for detecting or excluding neurocognitive impairment
Diagnosis Question* Sensitivity Specificity PPV NPV
NCI (ANI/ MND/ HAD/other) versus no NCI
(n = 957)
Memory 0.20 0.65 0.42 0.65
Slowing 0.10 0.89 0.54 0.63
Concentration 0.13 0.77 0.38 0.62
Total 0.32 0.80 0.51 0.63
HIV-associated NCI (ANI/MND/HAD) versus no NCI
(n = 932)
Memory 0.19 0.65 0.32 0.70
Slowing 0.07 0.89 0.36 0.69
Concentration 0.10 0.77 0.24 0.67
Total 0.24 0.80 0.35 0.70
Symptomatic NCI (MND/HAD/other) versus asymptomatic (no NCI/ ANI)
(n = 957)
Memory 0.22 0.64 0.17 0.91
Slowing 0.14 0.89 0.29 0.90
Concentration 0.21 0.79 0.22 0.91
Total 0.49 0.79 0.29 0.90
ANI, asymptomatic neurocognitive impairment; HAD, HIV-associated dementia; MND, mild neurocognitive disorder; NCI, neurocognitive impairment;
other, neurocognitive impairment related to confounders rather than associated with HIV infection.
*The three European AIDS Clinical Society (EACS) questions are shown, pertaining to memory, mental slowing and concentration. The PPV and NPV
shown relate to the answer, ‘yes, definitely’ to each of the three questions; ‘Total’ refers to the answer to at least one of the three questions being
‘yes, definitely’.
© 2019 The Authors.
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bias with complaining patients more agreeable to
NAMACO recruitment. Against this limitation, this study
did not aim to examine the prevalence of NCI or of cog-
nitive complaints but the association between the two.
Finally, while the Frascati criteria are currently the only
published criteria arrived at by consensus, we acknowl-
edge that using these criteria to classify NCI in our popu-
lation may have rendered the EACS screening questions
less sensitive or specific than they might be were other
measures of NCI severity to be applied.
We conclude that the EACS screening questions had an
NPV of 0.7 for excluding HIV-associated NCI in
NAMACO study participants using Frascati criteria. It
remains to be seen whether the PPV and NPV of these
questions improve if patients are classified according to
other, yet to be defined, NCI severity criteria. Currently,
these questions lack sensitivity and specificity as a tool
to guide clinicians as to which patients should be referred
for formal neuropsychological testing.
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